If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

KPTI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.24%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $2,476,921.87

Karyopharm Therapeutics Insider Trading History Chart

Karyopharm Therapeutics Share Price & Price History

^$3.52

▼ -0.4 (-10.20%)

As of 03/30/2023 01:00 AM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

Karyopharm Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Richard A Paulson	CEO	Sell	3,506	$3.16	$11,078.96	820,116
3/1/2023	Michael Mason	CFO	Sell	11,205	$3.03	$33,951.15	245,361
3/1/2023	Richard A Paulson	CEO	Sell	33,033	$3.03	$100,089.99	823,622
3/1/2023	Sohanya Roshan Cheng	EVP	Sell	11,239	$3.03	$34,054.17	210,687
3/1/2023	Stephen Mitchener	SVP	Sell	6,357	$3.03	$19,261.71	128,313
2/15/2023	Stuart Poulton	EVP	Sell	5,869	$3.19	$18,722.11	64,131
1/4/2023	Richard A Paulson	CEO	Sell	3,922	$3.27	$12,824.94	608,605
12/5/2022	Richard A Paulson	CEO	Sell	3,490	$5.17	$18,043.30	612,527
11/4/2022	Richard A Paulson	CEO	Sell	3,493	$4.54	$15,858.22	616,017
10/4/2022	Richard A Paulson	CEO	Sell	3,488	$5.87	$20,474.56	619,510
9/8/2022	Richard A Paulson	CEO	Sell	3,479	$5.23	$18,195.17	622,998
8/4/2022	Richard A Paulson	CEO	Sell	2,314	$4.48	$10,366.72	626,477
7/8/2022	Richard A Paulson	CEO	Sell	2,115	$5.18	$10,955.70	628,791
6/13/2022	Sohanya Roshan Cheng	Insider	Sell	1,551	$5.21	$8,080.71	89,949
6/10/2022	Deepika Pakianathan	Director	Sell	1,307	$6.00	$7,842.00	16,673
6/8/2022	Deepika Pakianathan	Director	Sell	325,977	$6.50	$2,118,850.50	18,731
6/7/2022	Richard A Paulson	CEO	Sell	2,542	$5.76	$14,641.92	630,906
6/3/2022	Michael Mason	CFO	Sell	601	$6.04	$3,630.04	138,509
2/7/2022	Jatin Shah	EVP	Sell	1,704	$9.86	$16,801.44
2/7/2022	Michael Kauffman	Director	Sell	6,764	$9.86	$66,693.04
2/7/2022	Michael Mason	CFO	Sell	3,947	$9.86	$38,917.42
2/7/2022	Sharon Shacham	Insider	Sell	6,707	$9.86	$66,131.02
12/2/2021	Stephen Mitchener	SVP	Sell	499	$6.69	$3,338.31
5/7/2021	Jatin Shah	EVP	Buy	23,250	$8.60	$199,950.00
5/6/2021	Garen G. Bohlin	Director	Buy	4,000	$7.82	$31,280.00	4,000
3/18/2021	Sharon Shacham	Insider	Sell	4,000	$12.39	$49,560.00	920,152
2/18/2021	Jatin Shah	EVP	Sell	1,186	$14.83	$17,588.38	51,791
2/18/2021	Sharon Shacham	Insider	Sell	9,495	$14.83	$140,810.85	776,452
12/18/2020	Mansoor Raza Mirza	Director	Sell	5,000	$18.00	$90,000.00	5,000
12/7/2020	Mansoor Raza Mirza	Director	Sell	20,000	$16.07	$321,400.00	20,000
12/1/2020	Christopher Brett Primiano	EVP	Sell	137,061	$17.53	$2,402,679.33	82,647
10/30/2020	Tanya Lewis	EVP	Sell	226	$15.58	$3,521.08	765
10/13/2020	Christopher Brett Primiano	EVP	Sell	39,271	$16.86	$662,109.06	43,199
10/12/2020	Michael Kauffman	CEO	Sell	7,500	$14.89	$111,675.00	555,122
9/8/2020	Christopher Brett Primiano	EVP	Sell	10,054	$14.98	$150,608.92	14,703
8/26/2020	John Demaree	Insider	Buy	7,500	$14.54	$109,050.00	7,500
8/17/2020	Michael Kauffman	CEO	Sell	1,477	$15.00	$22,155.00	555,122
7/15/2020	Jatin Shah	EVP	Sell	589	$19.46	$11,461.94	43,172
7/15/2020	Michael Kauffman	CEO	Sell	7,500	$19.43	$145,725.00	555,122
7/10/2020	Sharon Shacham	Insider	Sell	15,000	$19.27	$289,050.00
7/9/2020	Michael Kauffman	CEO	Sell	7,500	$19.53	$146,475.00	562,622
6/15/2020	Michael Kauffman	CEO	Sell	7,500	$16.37	$122,775.00	555,122
6/10/2020	Sharon Shacham	Insider	Sell	15,000	$16.60	$249,000.00
6/9/2020	Michael Kauffman	CEO	Sell	7,500	$18.50	$138,750.00	562,622
4/8/2020	Michael Kauffman	CEO	Sell	10,000	$18.61	$186,100.00	565,122

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Karyopharm Therapeutics (NASDAQ:KPTI)

96.13% of Karyopharm Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Karyopharm Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/23/2023	MetLife Investment Management LLC	29,394	$100K	0.0%	-29.0%	0.026%
2/28/2023	Voya Investment Management LLC	28,866	$98K	0.0%	-83.2%	0.025%
2/16/2023	Alliancebernstein L.P.	158,030	$0.54M	0.0%	+14.4%	0.195%
2/16/2023	Point72 Middle East FZE	47,257	$0.16M	0.0%	N/A	0.058%
2/16/2023	State of Wyoming	17,082	$58K	0.0%	+188.8%	0.021%
2/15/2023	MetLife Investment Management LLC	29,394	$100K	0.0%	-29.0%	0.036%
2/15/2023	Tejara Capital Ltd	501,562	$1.71M	1.0%	N/A	0.618%
2/15/2023	State of Wisconsin Investment Board	10,048	$34K	0.0%	-85.6%	0.012%
2/15/2023	Squarepoint Ops LLC	52,283	$0.18M	0.0%	N/A	0.064%
2/15/2023	Legal & General Group Plc	45,819	$0.16M	0.0%	+21.2%	0.056%
2/15/2023	Millennium Management LLC	351,543	$1.20M	0.0%	+33.8%	0.433%
2/15/2023	Morgan Stanley	1,289,437	$4.38M	0.0%	+19.4%	1.589%
2/15/2023	E Fund Management Co. Ltd.	36,504	$0.12M	0.0%	-20.5%	0.045%
2/15/2023	Algert Global LLC	82,668	$0.28M	0.0%	-13.8%	0.102%
2/15/2023	AQR Capital Management LLC	61,647	$0.21M	0.0%	-45.3%	0.076%
2/15/2023	Armistice Capital LLC	3,853,565	$13.10M	0.2%	N/A	4.748%
2/15/2023	Avidity Partners Management LP	9,633,911	$32.76M	0.7%	N/A	11.871%
2/14/2023	Point72 Asset Management L.P.	1,991,613	$6.77M	0.0%	+56,803.2%	2.454%
2/14/2023	Alyeska Investment Group L.P.	481,696	$1.64M	0.0%	N/A	0.594%
2/14/2023	Price T Rowe Associates Inc. MD	57,955	$0.20M	0.0%	+10.3%	0.071%
2/14/2023	Putnam Investments LLC	242,620	$0.83M	0.0%	N/A	0.299%
2/14/2023	Marshall Wace LLP	2,210,223	$7.52M	0.0%	+1,288.9%	2.723%
2/14/2023	Alpine Global Management LLC	17,081	$58K	0.0%	N/A	0.021%
2/14/2023	Two Sigma Investments LP	265,308	$0.90M	0.0%	+16.2%	0.327%
2/14/2023	Engineers Gate Manager LP	49,552	$0.17M	0.0%	+60.9%	0.061%
2/13/2023	Charles Schwab Investment Management Inc.	206,831	$0.70M	0.0%	+3.2%	0.255%
2/13/2023	Barclays PLC	1,046,712	$3.56M	0.0%	+129.8%	1.290%
2/13/2023	Renaissance Technologies LLC	189,300	$0.64M	0.0%	-38.6%	0.233%
2/13/2023	ExodusPoint Capital Management LP	1,106,132	$3.76M	0.1%	+56.4%	1.363%
2/13/2023	Martingale Asset Management L P	45,315	$0.15M	0.0%	N/A	0.056%
2/13/2023	Geode Capital Management LLC	1,377,128	$4.68M	0.0%	+3.5%	1.697%
2/13/2023	GSA Capital Partners LLP	82,162	$0.28M	0.0%	N/A	0.101%
2/13/2023	JPMorgan Chase & Co.	1,482,164	$5.04M	0.0%	+727.0%	1.826%
2/13/2023	Teacher Retirement System of Texas	28,597	$97K	0.0%	+22.4%	0.035%
2/10/2023	Opaleye Management Inc.	1,206,841	$4.28M	1.5%	N/A	1.487%
2/10/2023	Bank of America Corp DE	1,511,166	$5.14M	0.0%	+106.5%	1.862%
2/10/2023	New York Life Investment Management LLC	76,968	$0.26M	0.0%	+12.7%	0.095%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	432,278	$1.47M	0.0%	+178.1%	0.533%
2/10/2023	Advisor Group Holdings Inc.	8,906	$30K	0.0%	+134.3%	0.011%
2/10/2023	Moors & Cabot Inc.	12,200	$41K	0.0%	-42.3%	0.015%
2/9/2023	Principal Financial Group Inc.	56,805	$0.19M	0.0%	+186.5%	0.070%
2/9/2023	Monashee Investment Management LLC	481,696	$1.64M	0.7%	N/A	0.594%
2/9/2023	Citigroup Inc.	508,593	$1.73M	0.0%	-16.3%	0.627%
2/8/2023	UBS Group AG	523,259	$1.78M	0.0%	+364.9%	0.645%
2/8/2023	Swiss National Bank	259,150	$0.88M	0.0%	+52.9%	0.319%
2/8/2023	Russell Investments Group Ltd.	146,160	$0.50M	0.0%	+12.9%	0.180%
2/7/2023	State Board of Administration of Florida Retirement System	27,015	$92K	0.0%	-49.1%	0.033%
2/7/2023	Fox Run Management L.L.C.	28,823	$98K	0.0%	N/A	0.036%
2/6/2023	Los Angeles Capital Management LLC	101,917	$0.35M	0.0%	+29.6%	0.126%
2/3/2023	Birchview Capital LP	291,332	$0.99M	0.7%	+8.2%	0.359%
2/1/2023	Redwood Wealth Management Group LLC	33,230	$0.11M	0.1%	N/A	0.041%
2/1/2023	Janney Montgomery Scott LLC	10,000	$34K	0.0%	N/A	0.012%
1/30/2023	New York State Common Retirement Fund	49,074	$0.17M	0.0%	-27.2%	0.060%
1/26/2023	Dupont Capital Management Corp	22,957	$78K	0.0%	N/A	0.028%
1/23/2023	Allspring Global Investments Holdings LLC	26,599	$90K	0.0%	-27.2%	0.033%
1/12/2023	Hennion & Walsh Asset Management Inc.	144,353	$0.49M	0.0%	-47.8%	0.178%
12/8/2022	Bank of New York Mellon Corp	298,991	$1.63M	0.0%	+4.4%	0.368%
11/16/2022	Balyasny Asset Management LLC	595,558	$3.25M	0.0%	+592.0%	0.734%
11/16/2022	BNP Paribas Arbitrage SNC	762,520	$4.16M	0.0%	+30.5%	0.940%
11/15/2022	Alliancebernstein L.P.	138,130	$0.75M	0.0%	+17.0%	0.170%
11/15/2022	State Street Corp	9,010,339	$49.20M	0.0%	-13.0%	11.103%
11/15/2022	Jacobs Levy Equity Management Inc.	1,582,524	$8.64M	0.1%	+3.6%	1.950%
11/15/2022	Algert Global LLC	95,958	$0.52M	0.0%	-32.2%	0.118%
11/15/2022	Mercer Global Advisors Inc. ADV	11,425	$62K	0.0%	N/A	0.014%
11/15/2022	Two Sigma Advisers LP	831,300	$4.54M	0.0%	-15.7%	1.024%
11/15/2022	Two Sigma Investments LP	228,335	$1.25M	0.0%	-77.7%	0.281%
11/15/2022	Trexquant Investment LP	119,526	$0.65M	0.0%	+24.3%	0.147%
11/15/2022	Vanguard Group Inc.	4,813,399	$26.28M	0.0%	+14.0%	5.931%
11/15/2022	Price T Rowe Associates Inc. MD	52,532	$0.29M	0.0%	+39.5%	0.065%
11/15/2022	Marshall Wace LLP	159,137	$0.87M	0.0%	+591.9%	0.196%
11/15/2022	Engineers Gate Manager LP	30,790	$0.17M	0.0%	-37.1%	0.038%
11/15/2022	Frontier Capital Management Co. LLC	629,154	$3.44M	0.0%	-0.5%	0.775%
11/15/2022	Bank of New York Mellon Corp	298,991	$1.63M	0.0%	+4.4%	0.368%
11/15/2022	BlackRock Inc.	7,912,954	$43.20M	0.0%	-2.6%	9.751%
11/15/2022	Caxton Associates LP	71,903	$0.39M	0.1%	+41.0%	0.089%
11/15/2022	Commonwealth Equity Services LLC	10,165	$55K	0.0%	-21.7%	0.013%
11/14/2022	Royal Bank of Canada	11,175	$61K	0.0%	-16.1%	0.014%
11/14/2022	Tudor Investment Corp Et Al	60,064	$0.33M	0.0%	+10.2%	0.074%
11/14/2022	Cubist Systematic Strategies LLC	88,364	$0.48M	0.0%	-53.6%	0.109%
11/14/2022	Renaissance Technologies LLC	308,300	$1.68M	0.0%	-32.2%	0.380%
11/14/2022	Nuveen Asset Management LLC	1,971,048	$10.76M	0.0%	+4.0%	2.429%
11/14/2022	Altium Capital Management LP	750,000	$4.10M	1.5%	+7.1%	0.924%
11/14/2022	Rubric Capital Management LP	3,990,126	$21.79M	1.1%	-9.3%	4.917%
11/14/2022	UBS Oconnor LLC	271,219	$1.48M	0.0%	+19.2%	0.334%
11/14/2022	MetLife Investment Management LLC	41,409	$0.23M	0.0%	+78.4%	0.051%
11/14/2022	Metropolitan Life Insurance Co NY	4,622	$25K	0.0%	+73.9%	0.006%
11/14/2022	E Fund Management Co. Ltd.	45,924	$0.25M	0.0%	-12.8%	0.057%
11/14/2022	Hennion & Walsh Asset Management Inc.	276,422	$1.51M	0.1%	-3.6%	0.341%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	155,433	$0.85M	0.0%	+238.1%	0.192%
11/10/2022	ExodusPoint Capital Management LP	707,280	$3.86M	0.1%	+9.5%	0.872%
11/10/2022	Tower Research Capital LLC TRC	34,397	$0.19M	0.0%	+18.2%	0.042%
11/10/2022	UBS Group AG	112,546	$0.61M	0.0%	-64.6%	0.139%
11/8/2022	New York State Common Retirement Fund	67,406	$0.37M	0.0%	+37.9%	0.083%
11/7/2022	Nisa Investment Advisors LLC	5,700	$26K	0.0%	+612.5%	0.007%
11/4/2022	Prudential Financial Inc.	31,700	$0.17M	0.0%	-38.4%	0.040%
11/4/2022	Russell Investments Group Ltd.	129,415	$0.71M	0.0%	+18.6%	0.162%
11/3/2022	Teacher Retirement System of Texas	23,373	$0.13M	0.0%	+115.3%	0.029%
11/3/2022	Barclays PLC	455,464	$2.49M	0.0%	+456.0%	0.571%
11/2/2022	Los Angeles Capital Management LLC	78,657	$0.43M	0.0%	+321.1%	0.099%
11/1/2022	Rice Hall James & Associates LLC	909,083	$4.96M	0.3%	-30.9%	1.139%

Data available starting January 2016

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Today's Range

Now: $3.52

$3.50

$4.06

50 Day Range

MA: $3.31

$2.95

$3.92

52 Week Range

Now: $3.52

$2.45

$8.63

Volume

2,444,874 shs

Average Volume

2,697,873 shs

Market Capitalization

$398.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04

Who are the company insiders with the largest holdings of Karyopharm Therapeutics?: Karyopharm Therapeutics' top insider shareholders include:
Richard A Paulson (CEO)
Michael Mason (CFO)
Sohanya Roshan Cheng (EVP)
Stephen Mitchener (SVP)
Sohanya Roshan Cheng (Insider)
Stuart Poulton (EVP)
Deepika Pakianathan (Director)
Garen G Bohlin (Director)
Jatin Shah (EVP)
Michael Kauffman (Director)
Sharon Shacham (Insider)
Learn More about top insider investors at Karyopharm Therapeutics.
Who are the major institutional investors of Karyopharm Therapeutics?: Karyopharm Therapeutics' top institutional shareholders include:
Avidity Partners Management LP — 11.87%
Armistice Capital LLC — 4.75%
Marshall Wace LLP — 2.72%
Point72 Asset Management L.P. — 2.45%
Bank of America Corp DE — 1.86%
JPMorgan Chase & Co. — 1.83%
Learn More about top institutional investors of Karyopharm Therapeutics stock.
Which major investors are selling Karyopharm Therapeutics stock?: Within the previous quarter, KPTI stock was sold by these institutional investors:
Voya Investment Management LLC
Hennion & Walsh Asset Management Inc.
Renaissance Technologies LLC
Citigroup Inc.
State of Wisconsin Investment Board
AQR Capital Management LLC
Susquehanna International Group LLP
State Board of Administration of Florida Retirement System
Within the last year, company insiders that have sold Karyopharm Therapeutics company stock include:
Richard A Paulson (CEO)
Michael Mason (CFO)
Sohanya Roshan Cheng (EVP)
Stephen Mitchener (SVP)
Sohanya Roshan Cheng (Insider)
Stuart Poulton (EVP)
Deepika Pakianathan (Director)
Learn More investors selling Karyopharm Therapeutics stock.
Which major investors are buying Karyopharm Therapeutics stock?: In the last quarter, KPTI stock was purchased by institutional investors including:
Avidity Partners Management LP
Armistice Capital LLC
Marshall Wace LLP
Point72 Asset Management L.P.
JPMorgan Chase & Co.
Opaleye Management Inc.
Bank of America Corp DE
Barclays PLC
In the previous year, these company insiders have bought Karyopharm Therapeutics stock:
Richard A Paulson (CEO)
Michael Mason (CFO)
Learn More investors buying Karyopharm Therapeutics stock.

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

KPTI Insider Trading

Karyopharm Therapeutics Insider Trading History Chart

Karyopharm Therapeutics Share Price & Price History

Karyopharm Therapeutics Insider Trading History

SEC Filings (Institutional Ownership Changes) for Karyopharm Therapeutics (NASDAQ:KPTI)

Institutional Buying and Selling by Quarter

Karyopharm Therapeutics Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Karyopharm Therapeutics?

Who are the major institutional investors of Karyopharm Therapeutics?

Which major investors are selling Karyopharm Therapeutics stock?

Which major investors are buying Karyopharm Therapeutics stock?